Monoclonal antibodies raised against the Junín virus glycoprotein show broad reactivity and provide protection in vivo
11 affiliations
- 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 2Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 3Department of Biotechnology & Bioengineering, Sandia National Laboratory, Livermore, California, USA
- 4Texas Biomedical Research Institute, San Antonio, Texas, USA
- 5Southwest National Primate Research Center, San Antonio, Texas, USA
- 6Kemp Proteins, LLC, Frederick, Maryland, USA
- 7Battelle Biomedical Research Center, West Jefferson, Ohio, USA
- 8Department of Biosecurity & Bioassurance, Sandia National Laboratory, Livermore, California, USA
- 9Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 10Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Vienna, Austria
- 11Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness at the Medical University of Vienna, Medical University of Vienna, Vienna, Austria
Abstract
Argentine hemorrhagic fever (AHF) is a disease caused by the Junín virus (JUNV) that can be fatal in 15%–30% of untreated cases. Although JUNV is the only arenavirus for which efficient therapy and vaccination have been established, its administration is limited. In this study, hybridoma technology was used to generate 30 mouse monoclonal antibodies (mAbs) against the glycoprotein complex (GPC) of JUNV. Of these 30 mAbs, 26 showed strong cross-binding to GPCs from various arenaviruses. In addition, nine mAbs demonstrated potent neutralizing activity in vitro with a 50% inhibitory concentration of less than 1 µg/mL against a replication-competent chimeric vesicular stomatitis virus expressing JUNV GPC (rVSV-JUNV), as well as the live attenuated JUNV vaccine strain Candid#1. Furthermore, when tested in vivo using a challenge model of rVSV-JUNV in Stat2−/− mice, five select mAbs significantly reduced viral loads in the spleen when administered prophylactically. Humanized versions of JUNV-1A2, JUNV-1D5, and JUNV-5B12 mAbs, which showed protection in vivo in the Stat2−/− surrogate model, were produced. These antibodies were evaluated in a guinea pig challenge model of AHF and showed protective efficacy. Escape experiments with these humanized antibodies, as well as previously characterized antibodies, GB03 and JUN1, using rVSV-JUNV resulted in the acquisition of amino acid changes in the GP1 part of the GPC, which directly contacts host receptor transferrin receptor 1, indicating these sites could be key for future therapies. In summary, we generated mAbs that may be valuable for antibody-guided vaccine design and therapeutic development.
IMPORTANCE: Junín virus (JUNV) is a highly pathogenic virus that causes Argentine hemorrhagic fever (AHF) and is classified as a category A pathogen due to its potential for aerosol transmission and the significant number of annual infections and deaths associated with it. Although effective treatments exist, such as convalescent immune plasma, their availability is limited, and they are ineffective when given after the first week of symptoms. This study is significant because it focuses on developing therapeutic monoclonal antibodies against JUNV with strong in vitro neutralizing activity and protection in both a surrogate mouse model and a guinea pig challenge model of AHF. This has led to promising antibody candidates that could be used as therapeutics to combat ongoing outbreaks.
Related
- A Multilevel Framework for Evaluating the Impact of Monoclonal Antibodies Against Respiratory Syncytial Virus in Daycare and Households
- Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer
- Evidence for cross-reactivity and protection against Bundibugyo virus disease after heterologous vaccination: a systematic review and meta-analysis
- Novel monoclonal antibodies for an activated protein C cleavage neoepitope of coagulation factor Va
- Editorial: Monoclonal antibodies in treating multiple sclerosis (MS), and related diseases
BibTeX
@article{alzua2026monoclonal,
title = {{Monoclonal antibodies raised against the Junín virus glycoprotein show broad reactivity and provide protection in vivo}},
author = {Garazi Pena Alzua and Sharon Jan and Fatima Amanat and Grecia A. Sandoval and Christopher A. Sumner and Stephen Won and Anna L. Lara and Anupama Sinha and Brooke N. Harmon and Elizabeth B. Allmon and Kendra J. Alfson and Yenny Goez-Gazi and John W. Dutton and Ricardo Carrion and Sneha Rangarajan and Melissa C. Kerzic and Carter A. Mitchell and Chris M. Cirimotich and Dylan M. Johnson and Florian Krammer},
journal = {mBio},
year = {2026},
month = sep,
doi = {10.1128/mbio.00214-26},
url = {https://doi.org/10.1128/mbio.00214-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Monoclonal antibodies raised against the Junín virus glycoprotein show broad reactivity and provide protection in vivo
AU - Garazi Pena Alzua
AU - Sharon Jan
AU - Fatima Amanat
AU - Grecia A. Sandoval
AU - Christopher A. Sumner
AU - Stephen Won
AU - Anna L. Lara
AU - Anupama Sinha
AU - Brooke N. Harmon
AU - Elizabeth B. Allmon
AU - Kendra J. Alfson
AU - Yenny Goez-Gazi
AU - John W. Dutton
AU - Ricardo Carrion
AU - Sneha Rangarajan
AU - Melissa C. Kerzic
AU - Carter A. Mitchell
AU - Chris M. Cirimotich
AU - Dylan M. Johnson
AU - Florian Krammer
PY - 2026
DA - 2026/09/25
JO - mBio
DO - 10.1128/mbio.00214-26
UR - https://doi.org/10.1128/mbio.00214-26
AB - Argentine hemorrhagic fever (AHF) is a disease caused by the Junín virus (JUNV) that can be fatal in 15%–30% of untreated cases. Although JUNV is the only arenavirus for which efficient therapy and vaccination have been established, its administration is limited. In this study, hybridoma technology was used to generate 30 mouse monoclonal antibodies (mAbs) against the glycoprotein complex (GPC) of JUNV. Of these 30 mAbs, 26 showed strong cross-binding to GPCs from various arenaviruses. In addition, nine mAbs demonstrated potent neutralizing activity in vitro with a 50% inhibitory concentration of less than 1 µg/mL against a replication-competent chimeric vesicular stomatitis virus expressing JUNV GPC (rVSV-JUNV), as well as the live attenuated JUNV vaccine strain Candid#1. Furthermore, when tested in vivo using a challenge model of rVSV-JUNV in Stat2−/− mice, five select mAbs significantly reduced viral loads in the spleen when administered prophylactically. Humanized versions of JUNV-1A2, JUNV-1D5, and JUNV-5B12 mAbs, which showed protection in vivo in the Stat2−/− surrogate model, were produced. These antibodies were evaluated in a guinea pig challenge model of AHF and showed protective efficacy. Escape experiments with these humanized antibodies, as well as previously characterized antibodies, GB03 and JUN1, using rVSV-JUNV resulted in the acquisition of amino acid changes in the GP1 part of the GPC, which directly contacts host receptor transferrin receptor 1, indicating these sites could be key for future therapies. In summary, we generated mAbs that may be valuable for antibody-guided vaccine design and therapeutic development. IMPORTANCE: Junín virus (JUNV) is a highly pathogenic virus that causes Argentine hemorrhagic fever (AHF) and is classified as a category A pathogen due to its potential for aerosol transmission and the significant number of annual infections and deaths associated with it. Although effective treatments exist, such as convalescent immune plasma, their availability is limited, and they are ineffective when given after the first week of symptoms. This study is significant because it focuses on developing therapeutic monoclonal antibodies against JUNV with strong in vitro neutralizing activity and protection in both a surrogate mouse model and a guinea pig challenge model of AHF. This has led to promising antibody candidates that could be used as therapeutics to combat ongoing outbreaks.
SN - 2150-7511
ER -